Antiestrogen therapy of breast cancer

Marc E Lippman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Studies in vitro and in animal models have helped define the mechanism of action of antiestrogens and the differences in the physical properties of the various antiestrogens. Tamoxifen is the most widely studied antiestrogen. A review of 45 separate studies has shown a response rate to tamoxifen in advanced breast cancer that varies between 14% and 57%, with an overall response rate of 34%; prior therapy strongly influenced response rate. Menopausal status did not seem to influence response, and no dose-response relationship has been documented. Patients with estrogen-receptor-positive tumors are more likely to respond than those with estrogen-receptor-negative disease. Tamoxifen has been shown to be an unusually safe and well-tolerated drug. Studies of antiestrogens as adjuvants to local therapy of early breast cancer have generally produced encouraging results. More studies are needed, however, in order to define those subsets of patients who are most likely to benefit from adjuvant therapy with tamoxifen and to determine the most effective regimens.

Original languageEnglish
Pages (from-to)11-19
Number of pages9
JournalSeminars in Oncology
Volume10
Issue number4 SUPPL. 4
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Estrogen Receptor Modulators
Tamoxifen
Breast Neoplasms
Estrogen Receptors
Therapeutics
Animal Models
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Lippman, M. E. (1983). Antiestrogen therapy of breast cancer. Seminars in Oncology, 10(4 SUPPL. 4), 11-19.

Antiestrogen therapy of breast cancer. / Lippman, Marc E.

In: Seminars in Oncology, Vol. 10, No. 4 SUPPL. 4, 01.01.1983, p. 11-19.

Research output: Contribution to journalArticle

Lippman, ME 1983, 'Antiestrogen therapy of breast cancer', Seminars in Oncology, vol. 10, no. 4 SUPPL. 4, pp. 11-19.
Lippman ME. Antiestrogen therapy of breast cancer. Seminars in Oncology. 1983 Jan 1;10(4 SUPPL. 4):11-19.
Lippman, Marc E. / Antiestrogen therapy of breast cancer. In: Seminars in Oncology. 1983 ; Vol. 10, No. 4 SUPPL. 4. pp. 11-19.
@article{ef4e8642b9af4f388d0353f57e19df7d,
title = "Antiestrogen therapy of breast cancer",
abstract = "Studies in vitro and in animal models have helped define the mechanism of action of antiestrogens and the differences in the physical properties of the various antiestrogens. Tamoxifen is the most widely studied antiestrogen. A review of 45 separate studies has shown a response rate to tamoxifen in advanced breast cancer that varies between 14{\%} and 57{\%}, with an overall response rate of 34{\%}; prior therapy strongly influenced response rate. Menopausal status did not seem to influence response, and no dose-response relationship has been documented. Patients with estrogen-receptor-positive tumors are more likely to respond than those with estrogen-receptor-negative disease. Tamoxifen has been shown to be an unusually safe and well-tolerated drug. Studies of antiestrogens as adjuvants to local therapy of early breast cancer have generally produced encouraging results. More studies are needed, however, in order to define those subsets of patients who are most likely to benefit from adjuvant therapy with tamoxifen and to determine the most effective regimens.",
author = "Lippman, {Marc E}",
year = "1983",
month = "1",
day = "1",
language = "English",
volume = "10",
pages = "11--19",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 4",

}

TY - JOUR

T1 - Antiestrogen therapy of breast cancer

AU - Lippman, Marc E

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Studies in vitro and in animal models have helped define the mechanism of action of antiestrogens and the differences in the physical properties of the various antiestrogens. Tamoxifen is the most widely studied antiestrogen. A review of 45 separate studies has shown a response rate to tamoxifen in advanced breast cancer that varies between 14% and 57%, with an overall response rate of 34%; prior therapy strongly influenced response rate. Menopausal status did not seem to influence response, and no dose-response relationship has been documented. Patients with estrogen-receptor-positive tumors are more likely to respond than those with estrogen-receptor-negative disease. Tamoxifen has been shown to be an unusually safe and well-tolerated drug. Studies of antiestrogens as adjuvants to local therapy of early breast cancer have generally produced encouraging results. More studies are needed, however, in order to define those subsets of patients who are most likely to benefit from adjuvant therapy with tamoxifen and to determine the most effective regimens.

AB - Studies in vitro and in animal models have helped define the mechanism of action of antiestrogens and the differences in the physical properties of the various antiestrogens. Tamoxifen is the most widely studied antiestrogen. A review of 45 separate studies has shown a response rate to tamoxifen in advanced breast cancer that varies between 14% and 57%, with an overall response rate of 34%; prior therapy strongly influenced response rate. Menopausal status did not seem to influence response, and no dose-response relationship has been documented. Patients with estrogen-receptor-positive tumors are more likely to respond than those with estrogen-receptor-negative disease. Tamoxifen has been shown to be an unusually safe and well-tolerated drug. Studies of antiestrogens as adjuvants to local therapy of early breast cancer have generally produced encouraging results. More studies are needed, however, in order to define those subsets of patients who are most likely to benefit from adjuvant therapy with tamoxifen and to determine the most effective regimens.

UR - http://www.scopus.com/inward/record.url?scp=0021063176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021063176&partnerID=8YFLogxK

M3 - Article

C2 - 6367050

AN - SCOPUS:0021063176

VL - 10

SP - 11

EP - 19

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 4

ER -